Related Experiment Videos
Fluphenazine plasma levels and clinical response
S R Marder1, T Van Putten, M Aravagiri
1West Los Angeles Veterans Administration Medical Center, Brentwood Division, CA 90073.
Psychopharmacology Bulletin
|January 1, 1990
Summary
Monitoring fluphenazine plasma levels in schizophrenia patients revealed a significant link between higher levels and reduced psychotic exacerbations at 6 and 9 months. This suggests plasma level monitoring can guide fluphenazine decanoate dosage decisions.
Area of Science:
- Pharmacology
- Psychiatry
- Clinical Trials
Background:
- Schizophrenia treatment often involves long-acting injectable antipsychotics like fluphenazine decanoate (FD).
- Optimizing FD dosage is crucial for managing psychotic symptoms and minimizing exacerbations.
- Individual patient responses to FD can vary, necessitating personalized treatment approaches.
Purpose of the Study:
- To investigate the relationship between fluphenazine plasma levels and subsequent psychotic exacerbations in schizophrenic patients.
- To determine if fluphenazine plasma level monitoring can aid in adjusting FD dosage.
- To evaluate the predictive value of fluphenazine levels at different time points (3, 6, 9 months) for exacerbations.
Main Methods:
- A 2-year, double-blind, placebo-controlled study involving 39 schizophrenic patients.
- Patients received either 5 mg or 25 mg of fluphenazine decanoate (FD) every 14 days.
- Fluphenazine plasma levels were monitored at 3, 6, and 9 months, and analyzed for correlation with psychotic exacerbations using logistic regression and survival analysis (Cox models).
Main Results:
- Logistic regression showed a nonsignificant relationship at 3 months (p = .65) but significant relationships at 6 months (p = .04) and 9 months (p = .003).
- Survival analysis (Cox models) indicated significant relationships between fluphenazine levels and exacerbation risk at 6 months (p = .052) and 9 months (p = .0005), but not at 3 months (p = .65).
- Higher fluphenazine plasma levels were associated with a reduced risk of subsequent psychotic exacerbations.
Conclusions:
- Fluphenazine plasma level monitoring shows potential as a tool to guide FD dosage adjustments in schizophrenic patients.
- The predictive value of fluphenazine levels for exacerbations becomes significant at 6 and 9 months post-initiation.
- These findings support individualized therapeutic drug monitoring for optimizing long-acting injectable antipsychotic therapy.